In an evaluation of progression-free survival in which data for patients with increased CA-125 amounts were censored, as needed by regulatory firms, the median progression-free survival was 12.0 months in the control group but 18.0 months in the bevacizumab-throughout group . The approximated treatment influence on progression-free survival with bevacizumab throughout in comparison with control treatment was consistent across various prognostic factors . The median overall survival was 39.3, 38.7, and 39.7 months for the control group, the bevacizumab-initiation group, and the bevacizumab-throughout group, respectively .In conclusion, using data from a diverse and huge cohort of patients, we formulated a pharmacogenetic dose algorithm for warfarin that uses genotypes from two genes and medical variables to predict the stable therapeutic dose. This pharmacogenetic algorithm predicts the stable therapeutic dosage of warfarin much better than a fixed-dose strategy and much better than a scientific algorithm built from the same large data set. With the use of this algorithm and a definition of the ideal estimated dosage as a dose that differs by no more than 20 percent from the stable dose, the pharmacogenetic algorithm produced significantly better dosage estimates, with the greatest benefit seen in patients eventually requiring 21 mg or less of warfarin weekly and in those requiring 49 mg or even more weekly.